Press releases
Browse Canadian-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer
GSK announced today that Nova Scotia has become the first province to publicly reimburse Jemperli (dostarlimab for injection)
-
In honour of World COPD Day GSK promotes environmentally responsible disposal of used inhalers through health product stewardship program
To mark World Chronic Obstructive Pulmonary Disease (COPD) Day, GSK Canada is placing a spotlight on its partnership with HPSA
-
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms
-
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
GSK’s AREXVY has been approved in Canada for the prevention of lower respiratory tract disease (LRTD).
-
GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for JEMPERLI for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
GSK is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Jemperli
-
Data from new national study exposes oral corticosteroids overuse in Canadian patients with severe asthma
The ALERT study on uncontrolled severe asthma in Canada was recently presented at CHEST and at the ERS congress, showcasing real-world data
-
New survey reveals widespread lack of awareness about Respiratory Syncytial Virus (RSV) among older Canadians, despite health risks for this population
With healthy ageing becoming a topic of interest in Canada, new survey data highlighted gaps in knowledge among older Canadians.
-
Health Canada grants full approval to Jemperli for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
GSK today announced that Health Canada granted full approval for Jemperli (dostarlimab for injection)
-
Quebec’s Committee on Immunization (CIQ) recommends use of RSV vaccines, including AREXVY, for older adult populations at risk of severe outcomes
The Committee on Immunization of Quebec (Comité sur l’immunisation du Québec - CIQ) has recommended use of RSV
-
National Advisory Committee on Immunization (NACI) recommends RSV vaccines, including AREXVY, for older adult populations
The National Advisory Committee on Immunization (NACI) has strongly recommended RSV (respiratory syncytial virus) vaccines, including AREXVY
-
JEMPERLI receives recommendation from Canada’s Drug Agency for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer
Jemperli (dostarlimab for injection) has received a reimburse with conditions recommendation from Canada’s Drug Agency (CDA-AMC)
-
GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk
GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy,
-
GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada
Canadians aged 60 years and older can now better protect themselves against RSV disease.
-
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
GSK Canada submits respiratory syncytial virus (RSV) vaccine candidate for regulatory review
-
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
GSK announces purchase agreement with the Government of Canada for COVID-19 monoclonal antibody therapy, sotrovimab
-
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
